Clinical Trials
10 trialsNCT07013565 2026-05-20
ACCELERATE
New York Medical College
Phase 2 Recruiting
NCT03007030 2026-05-15
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06377566 2026-04-23
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03587844 2026-04-03
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05180097 2026-02-02
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05357794 2026-01-12
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07002216 2025-11-03
BrECADD
University of Miami
Phase 2 Recruiting
NCT04587687 2025-04-24
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT04378647 2024-02-26
BRESELIBET
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting